These two reports address the effects of varicella-zoster ... vaccine recipients than among placebo recipients (0.6% vs. 0.4%), for unknown reasons. The review authors recommend vaccine ...

“Preventing shingles through vaccination may, therefore ... “This data include many years of labs, medication administration, and orders for three million nursing home residents that we can then link ...

The varicella vaccine is highly effective, making chickenpox less common than it once was. After you get chickenpox, the virus stays in your body and can cause shingles, a painful rash ...

Thus, experts have worried that the pediatric varicella vaccine, by reducing childhood varicella rates, actually could increase zoster rates in the adult population. Researchers calculated ...

Shingrix, a shingles vaccine in the U.S., provides seven to 10 years of protection following the initial two-dose ...

SEATTLE, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with ...

Scientists have developed a vaccine for shingles, the unpleasant and often extremely painful condition which, it is estimated, affects around one third of the population at some point in their lives.

It is caused by a reactivation of the Herpes zoster virus - the virus that causes chicken pox. A vaccine against shingles was introduced in many countries about 18 years ago. Since then there has ...

Study published in Nature Medicine found that the recombinant shingles vaccine is linked to a reduced risk of dementia. This protective effect was particularly notable in females, suggesting a ...

Nova Scotia's Progressive Conservatives promised on Tuesday to introduce a universal shingles vaccine program for people 65 and older if re-elected Nov. 26, the latest in a series of targeted ...

Based upon these results, Curevo will advance amezosvatein into global Phase 3 trials in 2025 to address a market for shingles vaccination currently exceeding $4 billion annually. Amezosvatein and ...

Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine -- Ten shingles cases would have been expected ...